Estradiol/drospirenone

Estradiol/drospirenone
	Estradiol
	Drospirenone
Combination of
Estradiol	Estrogen
Drospirenone	Progestogen; Progestin; Antimineralocorticoid; Antiandrogen
Clinical data
Trade names	Angeliq
Other names	E2/DRSP; BAY-864891
Routes of; administration	By mouth
Drug class	Estrogen; Progestin; Progestogen; Antimineralocorticoid; Antiandrogen
Legal status
Legal status	US: ℞-only;
Identifiers
CAS Number	350818-73-4;

Estradiol/drospirenone (E2/DRSP), sold under the brand name Angeliq, is a combination of estradiol (E2), an estrogen, and drospirenone (DRSP), a progestin, antimineralocorticoid, and antiandrogen, which is used in menopausal hormone therapy, specifically the treatment of menopausal syndrome and osteoporosis, in postmenopausal women.^[1]^[2]^[3] It is taken by mouth and contains 0.5 to 1 mg E2 and 0.25 to 0.5 mg DRSP per tablet.^[1] The medication was approved in the United States in 2005.^[1] It is marketed widely throughout the world.^[4]

References

1 2 3 "ANGELIQ (drospirenone and estradiol) Prescribing Information" (PDF). Bayer HealthCare Pharmaceuticals Inc. U.S. Food and Drug Administration. February 2012. Archived from the original (PDF) on February 27, 2017.
↑ "Estradiol/Drospirenone - Bayer HealthCare Pharmaceuticals". AdisInsight.
↑ Rosano GM, Vitale C, Marazzi G, Volterrani M (February 2007). "Menopause and cardiovascular disease: the evidence". Climacteric. 10 (Suppl 1): 19–24. doi:10.1080/13697130601114917. PMID 17364594. S2CID 7305124.
↑ "Drospirenone and Estradiol: Uses, Side Effects & Warnings".

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by adding missing information.